Literature DB >> 27872531

Positive Peritoneal Lavage Cytology -Implications for Staging and Management of Gastric Cancer.

Suman B Koganti1, Satish Boddepalli2, Muralidhar Nambada2, Venu Madhav Thumma2, Bheerappa Nagari2, R A Sastry2.   

Abstract

The survival rates of gastric cancer patients with cytology-positive peritoneal lavage fluid without macroscopic dissemination (CY+/P-) is the same as that of patients with overt peritoneal metastasis.The 5-year survival rate of such patients is only 2%. The current study aims to highlight its significance in the staging of gastrointestinal malignancies and its implications for patient care. Prospective nonrandom analysis of peritoneal wash cytology in patients with gastrointestinal malignancies was conducted in the department of Surgical Gastroenterology, Nizams Institute of Medical Sciences, Hyderabad from January 2012 to June 2013. Descriptive statistics and ANOVA variance analysis was performed to estimate incidence, risk factors and the effect of surgery in causing peritoneal dissemination of malignancy. A total of 60 patients with operable gastric cancer underwent peritoneal lavage for evaluation of malignant cells. The incidence of Positive peritoneal lavage cytology was 8.3% (5/60).Four patients with positive lavage fluid belong to T3 stage (11.7%, p-0.309).Poorly differentiating and mucinous tumors had a higher incidence of positive cytology (18.1% and 25%).None of the patients with positive cytology had positive resection margin. Tumors with advanced T stage, lymph nodal involvement, lympho-vascular and perineural invasion have higher incidence of positive peritoneal cytology. Surgical handling has a negligible effect in peritoneal dissemination of tumor. Large scale studies are warranted to validate the findings and define it's role in management of gastric cancer.

Entities:  

Keywords:  AJCC-American joint committee on cancer; PPC-positive peritoneal wash cytology; TNM-tumor, node, metastasis

Year:  2016        PMID: 27872531      PMCID: PMC5097760          DOI: 10.1007/s13193-016-0527-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  22 in total

1.  Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer.

Authors:  P Vogel; J Rüschoff; S Kümmel; H Zirngibl; F Hofstädter; W Hohenberger; K W Jauch
Journal:  Dis Colon Rectum       Date:  2000-01       Impact factor: 4.585

2.  Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma.

Authors:  E Bando; Y Yonemura; Y Takeshita; K Taniguchi; T Yasui; Y Yoshimitsu; S Fushida; T Fujimura; G Nishimura; K Miwa
Journal:  Am J Surg       Date:  1999-09       Impact factor: 2.565

3.  D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer.

Authors:  X F Yu; Z G Ren; Y W Xue; H T Song; Y Z Wei; C M Li
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

4.  Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis.

Authors:  Takashi Marutsuka; Shinya Shimada; Kenji Shiomori; Naoko Hayashi; Yasushi Yagi; Takaaki Yamane; Michio Ogawa
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

5.  Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer.

Authors:  T Boku; Y Nakane; T Minoura; H Takada; M Yamamura; K Hioki; M Yamamoto
Journal:  Br J Surg       Date:  1990-04       Impact factor: 6.939

6.  Gastric cancer: a curable disease in Britain.

Authors:  H M Sue-Ling; D Johnston; I G Martin; M F Dixon; M R Lansdown; M J McMahon; A T Axon
Journal:  BMJ       Date:  1993-09-04

7.  Prognostic value of peritoneal cytology and the combination of peritoneal cytology and peritoneal dissemination in colorectal cancer.

Authors:  Takeshi Nishikawa; Toshiaki Watanabe; Eiji Sunami; Nelson H Tsuno; Joji Kitayama; Hirokazu Nagawa
Journal:  Dis Colon Rectum       Date:  2009-12       Impact factor: 4.585

8.  Pilot study of S-1 in patients with disseminated gastric cancer.

Authors:  Y Kitamura; K Hayashi; T Sasagawa; H Oguma; K Takasaki
Journal:  Drugs Exp Clin Res       Date:  2003

9.  Implications of peritoneal cytology for staging of early pancreatic cancer.

Authors:  A L Warshaw
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

10.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.

Authors:  Xiao-Jun Yang; Chao-Qun Huang; Tao Suo; Lie-Jun Mei; Guo-Liang Yang; Fu-Lin Cheng; Yun-Feng Zhou; Bin Xiong; Yutaka Yonemura; Yan Li
Journal:  Ann Surg Oncol       Date:  2011-03-23       Impact factor: 5.344

View more
  4 in total

1.  CMPD1 inhibited human gastric cancer cell proliferation by inducing apoptosis and G2/M cell cycle arrest.

Authors:  Yu Li; Depeng Zhang; Kaikai Yu; Yudong Hu; Qiong Wu; Feng Qian; Zishu Wang
Journal:  Biol Res       Date:  2018-04-16       Impact factor: 5.612

2.  The Morphological Analysis of Cells in the Peritoneal Washing Fluids of Patients with Gastric Cancer.

Authors:  Ren-Peng Jiang; Xue-Jiao Xiong; Xue-Shan Qiu; En-Hua Wang; Guang-Ping Wu
Journal:  Cell Transplant       Date:  2019-08-01       Impact factor: 4.064

Review 3.  The benefits of surgery plus extensive intraoperative peritoneal lavage (EIPL) for patients with gastric cancer compared with surgery alone: a systematic review and meta-analysis.

Authors:  Shujun Li; Laiyou Li; Bibo Tan; Jiajia Wang; Shan Xue
Journal:  Updates Surg       Date:  2021-06-25

4.  Rapid Detection of Free Cancer Cells in Intraoperative Peritoneal Lavage Using One-Step Nucleic Acid Amplification (OSNA) in Gastric Cancer Patients.

Authors:  Katarzyna Gęca; Karol Rawicz-Pruszyński; Jerzy Mielko; Radosław Mlak; Katarzyna Sędłak; Wojciech P Polkowski
Journal:  Cells       Date:  2020-09-25       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.